Gossamer Bio (GOSS) Non-Current Assets (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Non-Current Assets of $4.4 million for Q1 2026, down 14.69% year-over-year from $5.1 million in Q1 2025, and down 5.26% quarter-over-quarter from $4.6 million in Q4 2025.
Gossamer Bio (GOSS) Non-Current Assets (2018 - 2026) Analysis & Trends
Gossamer Bio's Non-Current Assets history runs 9 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 14.69% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $18.8 million (down 4.31% YoY), while the FY2025 annual figure was $4.6 million, down 14.79% from the prior year.
- Non-Current Assets for Q1 2026 stood at $4.4 million, down from $4.6 million in the prior quarter.
- The five-year high for Non-Current Assets was $13.9 million in Q1 2022, with the low at $2.5 million in Q2 2024.
- The 5-year median for Non-Current Assets is $5.4 million (2024), against an average of $7.1 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets plunged 69.59% in 2024, then soared 97.52% in 2025.
- Gossamer Bio's Non-Current Assets stood at $10.6 million in 2022, then slumped by 48.94% to $5.4 million in 2023, then grew by 0.13% to $5.4 million in 2024, then decreased by 14.79% to $4.6 million in 2025, then dropped by 5.26% to $4.4 million in 2026.
- Business Quant data shows GOSS's Non-Current Assets at $4.4 million in Q1 2026, $4.6 million in Q4 2025, and $4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Gossamer Bio | 50.34 Mn | -6.69 Mn | - | 4.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.14 Mn |
| Mar 31, 2026 | 4.36 Mn |
| Dec 31, 2025 | 4.61 Mn |
| Sep 30, 2025 | 4.83 Mn |
| Jun 30, 2025 | 5.03 Mn |
| Mar 31, 2025 | 5.11 Mn |
| Dec 31, 2024 | 5.40 Mn |
| Sep 30, 2024 | 6.61 Mn |
| Jun 30, 2024 | 2.55 Mn |
| Mar 31, 2024 | 4.09 Mn |
| Dec 31, 2023 | 5.40 Mn |
| Sep 30, 2023 | 6.44 Mn |
| Jun 30, 2023 | 8.37 Mn |
| Mar 31, 2023 | 9.49 Mn |
| Dec 31, 2022 | 10.57 Mn |
| Sep 30, 2022 | 11.51 Mn |
| Jun 30, 2022 | 13.16 Mn |
| Mar 31, 2022 | 13.91 Mn |
| Dec 31, 2021 | 11.88 Mn |
| Sep 30, 2021 | 13.05 Mn |